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ABSTRACT 
 
The MED1 subunit of the Mediator transcriptional coregulator complex coactivates 
GATA1 and induces erythropoiesis. Here, we show the dual mechanism of GATA1- 
and MED1-mediated transcription. MED1 expression levels in K562 erythroleukemia 
cells paralleled the levels of GATA1-targeted gene transcription and erythroid 
differentiation. An N-terminal fragment of MED1, MED1(1–602), which is incapable of 
interacting with GATA1, enhanced GATA1-targeted gene transcription and erythroid 
differentiation, and introduction of MED1(1–602) into Med1-/- mouse embryonic 
fibroblasts (MEFs) partially rescued GATA1-mediated transcription. The C-terminal 
zinc-finger domain of GATA1 interacts with the MED1(1–602)-interacting coactivator 
CCAR1, CoCoA, and MED1(681–715). CCAR1 and CoCoA synergistically enhanced 
GATA1-mediated transcription from the γ-globin promoter in MEFs. Recombinant 
GATA1, CCAR1, CoCoA, and MED1(1–602) formed a complex in vitro, and GATA1, 
CCAR1, CoCoA, and MED1 were recruited to the γ-globin promoter in K562 cells 
during erythroid differentiation. Therefore, in addition to the direct interaction between 
GATA1 and MED1, CoCoA and CCAR1 appear to relay the GATA1 signal to MED1, 
and multiple modes of the GATA1-MED1 axis may help to fine-tune GATA1 function 
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during GATA1-mediated homeostasis events. 
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INTRODUCTION 
A number of nuclear factors that activate or repress lineage-specific gene expression 
specifically regulate hematopoietic cell differentiation (reviewed in Cantor & Orkin 
2002; Kerenyi & Orkin 2010; Doré & Crispino 2011). GATA1, an erythroid and 
megakaryocytic lineage-specific transcription factor, is essential in erythropoiesis and 
megakaryopoiesis; GATA1 knockout mice show a lethal phenotype due to a complete 
block of erythromegakaryocytic precursor cell differentiation (Pevny et al. 1991; 
Shivdasani et al. 1997). GATA1 activates the transcription of genes involved in 
erythroid differentiation and proliferation and represses myeloid differentiation through 
its interaction with multiple activators and coregulators (reviewed in Cantor & Orkin 
2002; Kerenyi & Orkin 2010; Doré & Crispino 2011). Among the GATA1-interacting 
activators involved in erythroid differentiation are FOG1 (Tsang et al. 1997), KLF-1 
(Crossley et al. 1994), Sp1 (Merika & Orkin 1995) and RUNX1 (Elagib et al. 2003). 
GATA1 also interacts with LMO2 and forms a pentameric complex with SCL/Tal-1, 
E2A, LDB1, and LMO2, which activates transcription both from the GATA-binding site 
and from the E-box that neighbors GATA-binding site (Wadman et al. 1997). GATA1 
and PU.1, a myeloid-specific activator that binds GATA1, are mutually antagonistic, 
and repression of PU.1 by GATA1 blocks myelomonocytic differentiation of erythroid 
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precursors (Rekhtman et al. 1999; Zhang et al. 1999). Coactivators that act downstream 
of GATA1 include the histone acetyltransferases CBP/p300 (Blobel et al. 1998). These 
coactivators relax the chromatin structure through histone modification, and enable the 
preinitiation complex (PIC) to form on the GATA1-bound promoter. 
 
The Mediator transcriptional coregulator is an approximately 2-MDa multi-subunit 
polypeptide complex that integrates a variety of intracellular signals by physically and 
specifically forming a bridge between DNA-bound transcription factors and RNA 
polymerase II (Ito et al. 2002; Zhang et al. 2005; reviewed in Malik & Roeder 2010). 
The Mediator subunit MED1 was originally identified as a ligand-dependent coactivator 
of thyroid hormone receptor α (TRα) (Yuan et al. 1998). MED1 acts as specific 
coactivator of nuclear hormone receptors (NRs) (reviewed in Ito & Roeder 2001; Chen 
& Roeder 2011), C/EBPβ (Li et al. 2008), BRCA1 (Wada et al. 2004), and GATA 
family activators (Crawford et al. 2002; Stumpf et al. 2006), and plays an important role 
in the differentiation of distinct lineages of cells, including non-hematopoietic cells such 
as adipocytes (Ge et al. 2002; Ge et al. 2008) and mammary epithelial cells (Jiang et al. 
2010; Hasegawa et al. 2012). We previously showed that MED1 plays a crucial role in 
the ligand-dependent myelomonocytic differentiation of human promyelocytic leukemia 
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HL-60 cells, which differentiate into monocytes in the presence of 
1,25-dihydroxyvitamin D3 treatment, and differentiate into granulocytes in the presence 
of all-trans retinoic acid (ATRA) (Urahama et al. 2005). Med1-knockout mice are early 
embryonic lethal (Ito et al. 2000; Zhu et al. 2000), and analysis of Med1-knockout and 
Med1-conditional knockout mice showed that MED1 is crucial for normal erythroid 
differentiation during both the embryonic and adult stages (Stumpf et al. 2006; Stumpf 
et al. 2010). MED1 binds directly to GATA1 and activates the transcription of 
GATA1-targeted genes. However, the detailed mechanism of the nuclear signaling 
pathway is still unknown. Furthermore, a recent study of CD4-positive cell-specific 
Med1 conditional knockout mice suggested the significance of MED1 in intrathymic 
development of invariant natural killer T (iNKT) cells, although the precise underlying 
mechanism is not yet known (Yue et al. 2011). 
 
Cell cycle and apoptosis regulator 1 (CCAR1; also known as CARP-1), originally 
identified as a mediator of apoptosis signaling by retinoid CD437 (Rishi et al. 2003) and 
recently shown to be a coiled-coil coactivator (CoCoA)/calcium binding and coiled coil 
domain 1 (Calcoco1) C-terminal activation domain binding protein, activates estrogen 
receptor (ER)- and glucocorticoid receptor (GR)-mediated transcription through 
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simultaneous interaction with NRs and the N-terminus of MED1 (Kim et al. 2008). 
Therefore, CCAR1 constitutes an important bypass for Mediator recruitment to ER and 
GR targeted genes. CCAR1 and CoCoA also interact with p53 and activate 
p53-mediated transcription, probably by bypassing the interaction between p53 and 
MED1 (Kim et al. 2008). Furthermore, CCAR1 has been reported to be required for 
transcriptional activation by Wnt, β-catenin (Ou et al. 2009), and Ngn3 (Lu et al. 2012). 
 
This study demonstrates the role of, and mechanism underlying, MED1 action in 
GATA1-mediated transcription using K562 erythroleukemia cells, which were 
originally isolated from a patient with chronic myeloid leukemia (Lozzio & Lozzio 
1975). We confirm that MED1 is essential for optimal erythroid differentiation of 
erythroleukemic cells. We show, unexpectedly, that the direct interaction between 
GATA1 and MED1 is dispensable for GATA1-mediated transcription and erythroid 
differentiation, and we identified CCAR1 and CoCoA as a bypass between GATA1 and 
the MED1 subunit of Mediator, and suggest that the multiple modes of GATA1 
signaling might serve as a fine tuning mechanism for GATA1 action during homeostatic 
events that most probably include erythropoiesis. 
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RESULTS 
The Mediator subunit MED1 directs GATA1-induced transcription and erythroid 
differentiation in K562 cells 
The Mediator subunit MED1 acts as a GATA1-specific coactivator and promotes 
normal erythropoiesis (Stumpf et al. 2006). To analyze the mechanism of MED1 action 
in GATA1-mediated transcription, we used the hemin-induced and GATA1-dependent 
erythroid differentiation system of K562 erythroleukemia cells. When K562 cells were 
exposed to hemin, the cells differentiated toward the erythroid lineage, as evidenced by 
positive 3,3′-dimethoxybenzidine staining (Fig. 1A). During the first 3 days, 
transcription of GATA1-targeted erythroid differentiation marker genes, including genes 
encoding β-globin, γ-globin, porphobilinogen deaminase (PBGD), and 
5-aminolevulinate synthase (ALAS-E), was significantly activated (Fig. 1B). 
Unexpectedly, expression of Mediator subunits, including MED1 and MED24, were 
also notably (over 4-fold) induced (Fig. 1C). In contrast, expression of GATA1 and 
known GATA1-associated activators (KLF1, SCL, LMO2 and FOG1) was unchanged 
(GATA1, SCL, LMO2) or only slightly (up to 1.5-fold) increased (KLF1, FOG1) (Fig. 
S1). Because induced gene products often have an important physiological role, the 
Mediator complex could play a major role in GATA1-mediated erythroid 
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differentiation. 
 
Since the MED1 subunit, as well as other Mediator subunits, was reported to physically 
interact with GATA1 and coactivate GATA1-mediated transcription (Stumpf et al. 
2006), depletion of MED1 in K562 cells might impair GATA1 function and erythroid 
differentiation. Indeed, when MED1 expression was suppressed by RNA interference 
(Fig. 1D, E), hemin-induced transcriptional activation of the GATA1-targeted genes 
encoding β-globin, γ-globin, PBGD, and ALAS-E was strongly attenuated 3 days after 
hemin treatment (Fig. 1F). As a result, the number of erythroid-differentiated cells that 
were positive for 3,3′-dimethoxybenzidine staining was significantly attenuated during 3 
days of hemin treatment (Fig. 1G). In contrast, expression of GATA1 and associated 
activators was unchanged (KLF1, LMO2, FOG1) or rather slightly (up to 1.5-fold) 
increased (GATA1, SCL) (Fig. S2). When MED1 was knocked down in 
hemin-untreated K562 cells, expression of the GATA1-targeted genes was also strongly 
reduced (Fig. S3). These results indicate that MED1 plays a major role in 
GATA1-mediated transcription and erythroid differentiation in K562 cells. 
 
Human MED1(681–715) domain interacts with GATA1 
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It was previously reported that the middle portion of mouse (m) MED1 (amino acids 
622–701), mMED1(622–701), interacts with GATA1 (Stumpf et al. 2006). To narrow 
down the region of human (h) MED1 that interacts with GATA1, and to further analyze 
this interaction at the mechanistic level, serial binding assays were performed. 
HA-tagged recombinant mGATA1 was not pulled down by recombinant FLAG-tagged 
N-terminal and C-terminal hMED1 fragments [hMED1(1–552) and 
hMED1(715–1,581)] (Fig. S4A) immobilized to M2-agarose, which was in agreement 
with a previous report (Fig. 2A, B) (Stumpf et al. 2006). Next, a series of hMED1 
GST-fusion fragments (Fig. S4B) were tested for their interaction with recombinant 
HA-tagged mGATA1, and hMED1(681–715) was the shortest fragment tested that was 
found to significantly interact with mGATA1 (Fig. 2C). To confirm this interaction in a 
more physiological setting within mammalian cells, we next assessed it in a mammalian 
two-hybrid assay using Med1-/- MEFs, and the interaction between hMED1(681–715) 
and (both mouse and human) GATA1 was confirmed (Fig. 2D, E). 
 
hMED1(681–715) is dispensable for GATA1-mediated transcription and erythroid 
differentiation 
We next assessed the role of the GATA1-interacting region of hMED1(681–715) in 
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GATA1 function and erythroid differentiation. We first tested the effect of 
overexpressing various hMED1 fragments (Yuan et al. 1998; Sumitomo et al. 2010) by 
transfection with mammalian expression vectors into K562 cells (Fig. 3A). MED1 is a 
substoichiometric component of Mediator, and Mediator that is associated with RNA 
polymerase II core complex is enriched in the Mediator fraction containing the 
activator-bound MED1 (Zhang et al. 2005; reviewed in Malik & Roeder 2010). The free 
Mediator subunit is destabilized and subject to an enhanced turnover (Ito et al. 2002). 
When the FLAG-tagged mutant MED1 transfected in HeLa cells is immunopurified 
with anti-FLAG antibody beads, the isolated proteins contain stoichiometric amounts of 
mutant MED1 and other representative Mediator subunits (Ge et al. 2002). Hence, 
overexpression of MED1 corresponds to saturation of MED1 in the Mediator complex 
and may lead to enhanced GATA1-induced transcription. 
 
When full-length hMED1 [hMED1(1–1,581)] was overexpressed in K562 cells (Fig. 3B, 
C), transcription of GATA1-targeted genes was prominently activated 3 days after 
transfection (Fig. 3D), and the number of differentiated cells stained with 
3,3′-dimethoxybenzidine increased for 4 days after transfection (Fig. 3E). MED1 has 2 
closely located LxxLL NR recognition motifs (NR boxes) (Yuan et al. 1998). We then 
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overexpressed 2 N-terminal hMED1 fragments, hMED1(1–602), which lacks the NR 
boxes, and hMED1(1–703), which contains the NR boxes. Both of these mutants lack 
the binding domain for, hence the capacity of binding to, GATA1 (Fig. 3A). The 
exogenously overexpressed MED1 truncations and the endogenous MED1 were 
incorporated in the Mediator competitively according to their molar ratios (Fig. 3C). 
Unexpectedly, overexpression of either of these mutant MED1 fragments also enhanced 
transcriptional activation of GATA1-targeted genes to levels similar to, but possibly not 
as prominent as, those following overexpression of full-length hMED1 (Fig. 3D). 
Erythroid differentiation, as assessed by the number of cells stained with 
3,3′-dimethoxybenzidine, was also enhanced by overexpression of hMED1(1–602) and 
hMED1(1–703), but the enhancement may not have been as prominent as when 
full-length hMED1 was overexpressed (Fig. 3E). Of note, introduction of 
siRNA-resistant MED1(1–602) to MED1-knockdown K562 cells rescued the attenuated 
GATA1-targeted gene transcription and erythroid differentiation (Fig. 1F, G). 
 
Meanwhile, hMED1(1–602) overexpression caused expression of GATA1 and 
associated activators unchanged (SCL, LMO2, FOG1) or minimally changed (GATA1, 
KLF1) (Fig. S5). In contrast, in the absence of hemin, expression of GATA1-targeted 
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genes did not change (γ-globin, β-globin, PBGD) or only slightly elevated (ALAS-E) by 
MED1(1–602) overexpression. Expression of GATA1 and associated activators also did 
not change (KLF1, FOG1) or marginally elevated (SCL, LMO2, GATA1) (Fig. S6). 
These results suggest that direct interaction between GATA1 and MED1 is dispensable, 
and that the N-terminal hMED1(1–602) domain is sufficient for hemin-induced 
erythroid differentiation and associated coactivation of GATA1, but that the C-terminal 
domain of MED1 that contains the GATA1-binding motif might be necessary for full 
activation of GATA1-mediated erythroid differentiation. 
 
MED1-mediated transcription initiation of the γ-globin promoter 
The human γ-globin promoter includes 2 consensus sequences for GATA1 (−175 to 
−171 and −189 to −185); when GATA1 binds to these sequences, γ-globin transcription 
is strongly induced (Martin et al. 1989). To assess the mechanism underlying MED1 
function in GATA1-mediated transcription, luciferase reporter assays using the human 
γ-globin promoter (–299 to +37) were employed. 
 
The reporter assays showed that transcription in Med1+/+ MEFs was strongly activated 
(up to 7-fold) in the presence of mGATA1 in a dose-dependent manner (Fig. 4A). When 
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a fixed amount of mGATA1 (100 ng) was added, transcription was 4-fold higher in the 
Med1+/+ MEFs than in the absence of mGATA1; however, transcription was only 
modestly increased in Med1-/- MEFs (1.5-fold) compared to transcription in these cells 
in the absence of mGATA1, even though residual activation might occur in these cells 
(Fig. 4B). Therefore, MED1 appeared to be necessary for optimal GATA1-mediated 
transcription, even though a redundant mechanism that does not require MED1 might 
exist. Introduction of exogenous full-length hMED1(1–1,581) into Med1-/- MEFs 
rescued GATA1-dependent transactivation to wild-type levels (Fig. 4B). Next, various 
hMED1 mutants were cotransfected to determine the MED1 domain(s) responsible for 
GATA1-dependent activation (Fig. 4B). Both MED1(1–602) and MED1(1–703) 
significantly restored GATA1-mediated transcriptional activation to similar levels in a 
dose-dependent manner; however, transcription did not appear to be fully restored 
compared to transcription levels when full-length MED1(1–1,581) was introduced (Fig. 
4B). This difference might reflect the contribution of the direct interaction between 
MED1(681–715) and GATA1. In contrast, MED1(592–1,581), which is incapable of 
complex formation (Ge et al. 2008), was unable to restore any transcriptional activity 
(Fig. 4B). 
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These data might suggest that both MED1(1–602) and MED1(603–1,581) contribute to 
γ-globin transcription. MED1(1–602) appears to stimulate GATA1-mediated 
transactivation independent of direct interaction with GATA1, while MED1(603–1,581) 
possibly contributes to GATA1-mediated transactivation through the direct interaction 
of GATA1 and MED1(681–715). The results also indicate that the MED1 NR boxes are 
dispensable for GATA1 function. 
 
CCAR1 enhances GATA1-mediated transactivation 
Given that MED1(1–602) enhanced GATA1-initiated transactivation, a GATA1 
signaling mechanism that bypasses its interaction with MED1 appears to exist. In the 
case of NRs, the bypass molecule CCAR1 reportedly simultaneously interacts with both 
the NRs (ERs and GR) and with the N-terminus of MED1(1–670), and mediates a 
bypass pathway that does not require the direct interaction between the NRs and the 
MED1 NR boxes (Kim et al. 2008). Based on this information, we hypothesized that 
CCAR1 might also mediate a bypass pathway between GATA1 and MED1, and tested 
this hypothesis. 
 
Luciferase reporter assays using the human γ-globin promoter (–299 to +37) in Med1+/+ 
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MEFs showed that CCAR1 alone enhanced reporter activity in a dose-dependent 
manner. When GATA1 was coexpressed with CCAR1, reporter activity was further 
enhanced (Fig. 4C). It is known that GATA1 interacts with the chromatin-modifying 
coactivator p300 (Blobel et al. 1998) and that p300 interacts with CoCoA (Kim et al. 
2006), a partner activator of CCAR1. Therefore, p300 could indirectly recruit CCAR1 
and MED1 to GATA1 for transactivation. However, the addition of p300 did not further 
enhance reporter activity in this system (Fig. 4C). Therefore, CCAR1 might act as a 
coactivator of not only NRs, but also GATA1, possibly through a p300-independent 
mechanism. 
 
MED1 interacts with both the N- and C-terminal halves of CCAR1 
Since a previous report suggested that the N-terminus of MED1 interacts with CCAR1 
(Kim et al. 2008), we attempted to further analyze this interaction. A mammalian 
two-hybrid assay was used to identify which parts of CCAR1 interact with MED1. 
Indeed, Gal4-MED1 specifically interacted with both VP16-CCAR1(1–657) and 
VP16-CCAR1(640–1,146) (Fig. 4D). Therefore, MED1 appears to interact with both 
the N- and C-terminal halves of CCAR1. 
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The C-terminal zinc finger (CF) domain of GATA1 is necessary for the direct 
interaction with the C-terminus of CCAR1 and MED1 
Since CCAR1 enhanced GATA1-mediated transcription irrespective of p300, we asked 
if CCAR1 could directly convey the GATA1 signal to MED1, analogous to the case 
with NRs. Indeed, a GST-pull down assay showed that GATA1 directly interacts with 
CCAR1 in vitro (Fig. 5A). A mammalian two-hybrid assay in Med1-/- MEFs confirmed 
that this interaction takes place within mammalian cells, and showed that this 
intranuclear interaction required the C-terminal half of CCAR1 [CCAR1(640–1,146)] 
(Fig. 5B). 
 
To analyze the mechanism of GATA1 action in CCAR1-mediated transcription, we next 
asked which domain of GATA1 interacts with CCAR1. GATA1 contains 2 zinc finger 
domains, an N-terminal zinc finger (NF) and a C-terminal zinc finger (CF), which bind 
DNA and various activators and cofactors, including FOG1 and LMO2 (the NF domain), 
and PU.1, EKLF, and Sp1 (the CF domain) (Wilkinson-White et al. 2011; Rekhtman et 
al. 1999; Merika & Orkin 1995) (Fig. 5C). Serial GST-pull down assays and 
mammalian two-hybrid assays in Med1-/- MEFs, determined that CCAR1 interacted 
with GATA1(249–413) but not with GATA1(316–413) (Fig. 5D, E). Therefore, 
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GATA1(249–315), the CF domain of GATA1, was necessary for the interaction with 
CCAR1. However, GATA1(249-315) was not enough for the interaction, and either the 
N-terminal [GATA1(200-315)] or C-terminal [GATA1(249-330)] extension outside of 
GATA1(249-315) was necessary (Fig. 5I). 
 
Regarding the direct interaction between GATA1 and MED1, a previous report 
suggested that MED1 interacts with the GATA1 NF domain (Stumpf et al. 2006). We 
also assessed their interaction using GST-pull down assays and mammalian two-hybrid 
assays, as were used for the analyses of CCAR1 interaction (above). Unexpectedly, in 
our relatively stringent system, neither mGATA1(1–257) nor hGATA1(1–257) 
interacted with MED1. Indeed, both mouse and human GATA1(249–413) interacted 
with hMED1, but neither mouse nor human GATA1(316–413) did (Fig. 5F-H). 
Therefore, GATA1(249–315), which contains the CF domain, was required for specific 
interaction with MED1. However, as was the case for CCAR1, GATA1(249–315) was 
not enough for this interaction, and either N-terminal [GATA1(200–315)] or C-terminal 
[GATA1(249–330)] extension was necessary (Fig. 5I). The reason for this discrepancy 
might be the differences in the experimental procedures; however, the physical 
interaction of the GATA1 containing its CF domain with both CCAR1 (above) and 
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MED1 appears to be relevant in vivo. 
 
The AD2 domain of CoCoA, a partner of CCAR1, interacts with the GATA1 CF 
domain 
CoCoA is a known dimerization partner of CCAR1 (Kim et al. 2008) that acts as a 
transcriptional coactivator for some activators, including NRs (Kim et al. 2003), 
β-catenin (Yang et al. 2006a; Yang et al. 2006b), aryl hydrocarbon receptor (Kim et al. 
2004), and p53 (Kim et al. 2008). Indeed, during hemin-induced differentiation of K562 
cells, CoCoA expression was prominently (4-fold) induced after 2 days, while 
expression of CCAR1 only minimally changed (Fig. S1). Expression of CoCoA was 
modestly induced when MED1 was knocked down (Fig. S2), and when MED1(1–530) 
was overexpressed both in the presence and absence of hemin (Fig. S5, S6). Therefore, 
CoCoA might have an important role in MED1-mediated transcriptional control, and we 
next assessed the role of CoCoA in GATA1-mediated activation. First, the interaction 
between CCAR1 and CoCoA was analyzed by mammalian two-hybrid assays in Med1-/- 
MEFs. Consistent with a previous study that utilized GST-pull down assays (Kim et al. 
2008), Gal4-CoCoA interacted with VP16-CCAR1(1–657) in Med1-/- MEFs, and 
VP16-CCAR1 interacted with CoCoA(501–691) (Fig. 6A, B). Therefore, we confirmed 
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that the N-terminal half of CCAR1 interacts specifically with the C-terminus of CoCoA. 
 
CoCoA is composed of 3 domains, CoCoA(1–190), an N-terminal activation domain 2 
(AD2), CoCoA(144–513), a coiled-coil domain, and CoCoA(501–691), a C-terminal 
AD1 (Yang et al. 2008) (Fig. 6H). NR signaling may be conveyed through the CoCoA 
coiled-coil domain via SRC2/GRIP1 (Kim et al. 2003), while β-catenin and p300 
interact with both the AD2 and AD1 of CoCoA (Kim et al. 2006; Yang et al. 2006a; 
Yang et al. 2006b). We now add CCAR1 to the list of specific CoCoA AD1-interacting 
proteins (Fig. 6G). 
 
We next tested if CoCoA could interact with GATA1. Intriguingly, serial GST-pull down 
assays and mammalian two-hybrid assays (as described above) demonstrated a specific 
and significant interaction between CoCoA and the GATA1(249–315) that corresponds 
to the CF domain (Fig. 6C-E). Then, serial GST-pull down assays were performed to 
determine which domain of CoCoA interacted with CCAR1. CoCoA(45–125), which 
corresponds to activation domain 2 (AD2) of CoCoA, was found to bind specifically to 
GATA1 (Fig. 6E). Mammalian two-hybrid assays confirmed the intracellular interaction 
between GATA1 and CoCoA(45–125) (Fig. 6F). These results indicate that CoCoA AD2 
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may interact with GATA1, CoCoA AD1 interacts with CCAR1 (Fig. 6G), and that the 
GATA1 CF domain serves as a docking surface for multiple coactivators, including 
CoCoA, CCAR1, and MED1. 
 
GATA1, MED1, CCAR1, and CoCoA are recruited to the γ-globin promoter during 
erythroid differentiation 
Since CCAR1 appeared to be involved in GATA1- and MED1-mediated transcriptional 
activation and erythroid differentiation independent of the direct interaction between 
GATA1 and MED1, and since CoCoA might be a GATA1- and CCAR1-interacting 
molecule, we next asked if these molecules were actually recruited to the γ-globin 
promoter during erythroid differentiation of K562 cells. When K562 cells were tested 
using chromatin immunoprecipitation (ChIP) assays before and after treatment with 
hemin, GATA1, MED1, CCAR1, and CoCoA were all recruited onto the γ-globin 
promoter at the GATA1-binding sites after 2 and 3 days during erythroid differentiation 
(Fig. 7A). Therefore, the intrinsic GATA1 binding sites were occupied by GATA1, 
CCAR1/CoCoA, and Mediator during the transcriptional activation of the γ-globin 
promoter. Next, the occupancies of GATA1, MED1, CCAR1 and CoCoA were assessed 
chronologically for 24 h so that the order of the occupancies may be more apparent. 
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After 12 h, the occupancy of CCAR1 and MED1 began to increase, followed by CoCoA 
recruitment at 24 h. The occupancy of GATA1 appeared unchanged during this period 
(Fig. 7B). Thus, during the first day, GATA1 already associated with the promoter 
appeared to be used for recruitment of CCAR1 and MED1. After 2 days, together with 
the enhanced recruitment of GATA1, the occupancy of all of these cofactors increased. 
While the occupancy of CCAR1 appeared to reach the maximum after 2 days, more 
CoCoA and MED1 were recruited after 3 days (Fig. 7A), concurrently with the induced 
expression of CoCoA and MED1 (Fig. 1C, Fig. S1). 
 
To prove that GATA1 is the platform for recruitment of these cofactors, knockdown of 
GATA1 was performed followed by ChIP assays. Indeed, 3 days after GATA1 was 
knocked down in hemin-treated K562 cells (Fig. 7C, D), the occupancy of CoCoA and 
MED1 was reduced and CCAR1 did not increase (Fig. 7E), even though expression of 
these cofactors was upregulated (Fig. S7). Hence, DNA-bound GATA1 appeared to be 
the interface for recruitment of these cofactors. 
 
GATA1, CCAR1/CoCoA, and MED1(1–602) simultaneously associate 
Since GATA1, CCAR1/CoCoA, and MED1 interact with one another both in vitro and 
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in vivo and since they are recruited to endogenous GATA1-binding sites during 
transcription, we next asked if these molecules could associate. We prepared 
recombinant CCAR1, CoCoA, and MED1(1–602) and performed GST-pull down assays 
using recombinant GST-GATA1(200–315), which contains the zinc finger domains. 
Although GST-GATA1(200–315) did not interact with MED1(1–602) alone (Fig. 8A, 
lane 4), it did interact with CCAR1 and MED1(1–602) (Fig. 8A, lane 2), indicating that 
CCAR1 can simultaneously interact with MED1 and GATA1. When CoCoA was also 
added, it efficiently co-purified with CCAR1 and MED1(1–602) (Fig. 8A, lane 3). 
 
It is known that GATA1 interacts with endogenous Mediator through MED1 subunit in 
vivo (Stumpf et al. 2006). We next asked if endogenous GATA1 and CCAR1/CoCoA 
associate during transcription. When total cell lyates of hemin-treated K562 cells were 
used for immunoprecipitation with the anti-GATA1 antibody, both CCAR1 and CoCoA 
were co-immunoprecipitated together with GATA1 (Fig. 8B). Therefore, endogenous 
GATA1 and CCAR1/CoCoA associate during GATA1-mediated transcription and 
erythroid differentiation. 
 
These results indicate that GATA1, CCAR1/CoCoA, and MED1 can form a complex, at 
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least transiently, and may contribute to GATA1- and MED1-mediated transcriptional 
activation independent of the direct interaction of GATA1 and MED1. 
 
GATA1, CCAR1, and CoCoA cooperatively activate transcription at the γ-globin 
promoter 
Since CoCoA might be involved in GATA1-mediated transcriptional activation, we next 
tested the role of CoCoA at the γ-globin promoter using luciferase reporter assays in 
Med1+/+ MEFs. CoCoA modestly enhanced γ-globin promoter activity in a 
dose-dependent manner (up to 1.7 times the basal level). When a small amount of 
GATA1 (20 ng) was added, transcriptional activation was enhanced in a CoCoA 
dose-dependent manner (up to 2.5 times) (Fig. 8C). When small amounts of GATA1 (20 
ng), CCAR1 (20 ng), and/or CoCoA (20 ng) were added to Med1+/+ MEFs in various 
combinations, any combination of 2 components significantly activated transcription 
(up to 2 times the basal level). When all 3 components were added altogether, 
transcriptional activation was further enhanced (4 times the basal level) (Fig. 8D). 
However, GATA1- and CCAR1/CoCoA-mediated transactivation was not induced in 
Med1-/- MEFs, indicating that the action of CCAR1/CoCoA is dependent on MED1 (Fig. 
8D). These results indicate that the CCAR1/CoCoA pair can cooperatively enhance 
24 
 
GATA1- and MED1-mediated transcriptional activation. 
 
We next assessed the requirement of CCAR1 and CoCoA for GATA1-dependent gene 
transcription during K562 cell differentiation by overexpression of these genes (Fig. S8). 
Indeed, CoCoA overexpression did enhance expression of GATA1-targeted and 
erythroid marker genes, among which γ-globin expression was prominent, as well as 
some GATA1-associated regulators (FOG1, KLF1, SCL) (Fig. 8E, Fig. S9). However, 
overexpression of CCAR1 did not enhance transcription of these genes, possibly 
indicating, consistent with the fact that CCAR1 was not induced during differentiation 
of K562 cells (Fig. S1), that endogenous CCAR1 was sufficient for this function, while 
CoCoA might be a limiting factor in this process. Indeed, when CoCoA was knocked 
down in K562 cells (Fig. 8F, G), expression of GATA1-targeted genes including 
γ-globin and β-globin was significantly reduced during erythroid differentiation (Fig. 
8H). Since hCCAR1 siRNA that efficiently attenuates endogenous CCAR1 in K562 
cells was unavailable, we tested human γ-globin promoter in Med1-/- MEFs. When 
endogenous CCAR1 was knocked down in these cells (Fig. 8I, J), GATA1 function was 
attenuated. While the addition of MED1(1–602) prominently enhanced the reporter 
activity in control cells, the activity was unchanged when CCAR1 was downregulated 
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(Fig. 8K). These results further confirm that CCAR1 and CoCoA have an important role 
in GATA1- and MED1-mediated transcription.
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DISCUSSION 
In the process of analyzing the role of MED1 in GATA1-mediated transcriptional 
activation in K562 cells, we gathered evidence that the direct interaction between 
MED1 and GATA1 is partially redundant, and that the CCAR1/CoCoA pair can bypass 
the need for this interaction in GATA1- and MED1-mediated transcriptional activation 
(Fig. 9). This bypass pathway constitutes a novel post-GATA1 intranuclear signaling 
pathway that might be of biological significance. 
 
The transcriptional bypass CCAR1/CoCoA coactivator as a secondary coactivation 
system 
Previous studies indicated that CoCoA, identified as a NR-specific coactivator, interacts 
with both SRC2/GRIP1 and p300 (Kim et al. 2003; Kim et al. 2006). Although the 
precise mechanisms underlying CoCoA action in transcriptional activation are not yet 
known, CoCoA might serve as an intermediary, connecting activator signaling to 
histone-modifying coactivators (Kim et al. 2006). CCAR1, identified as partner of 
CoCoA and as a bypass molecule for ER and GR, conveys intranuclear post-receptor 
signal to Mediator via MED1 (Kim et al. 2008). Thus, the CCAR1 and CoCoA pair 
appears to function cooperatively, and in multiple, distinct, and supplementary ways, to 
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coactivate NR functions. It is conceivable that transactivation induced by p53, β-catenin, 
and Ngn-3 is similarly mediated by the CCAR1 and CoCoA pair, where CCAR1 and 
CoCoA play either a supplementary or major role in coactivation. 
 
This study re-identifies GATA1 as a novel activator that is driven by the 
CCAR1/CoCoA pair. In addition to the role of CCAR1 (and CoCoA) as a molecular 
bridge between GATA1 and MED1 during recruitment of RNA polymerase II 
holoenzyme to the promoter and PIC formation, its interacting partner CoCoA might 
simultaneously recruit chromatin remodeling complex(es), which may contribute to 
relaxation of nucleosome structures and enable recruitment of the basal transcriptional 
machinery. Therefore, the CCAR1/CoCoA pair might constitute a secondary 
coactivation machinery beyond primary coactivators, which include chromatin 
modifying coactivators (p160 coactivators, histone acetyltransferases [e.g., CBP and 
p300], and histone methyltransferases [e.g., CARM1 and PRMT1]) and Mediator. The 
multiple layers in the coactivation systems proposed here are probably used for efficient 
transactivation in vivo not only by GATA1, but also by other activators, including NRs 
and p53. 
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Model for GATA1-induced transcriptional activation 
Besides its association with MED1 and CCAR1/CoCoA (Kim et al. 2008; this study), 
GATA1 is known to interact with acetyltransferase coactivators (e.g., CBP/p300) 
(Blobel et al. 2998). This interaction is reminiscent of the one with NRs, and the 
multistep activation model of GATA1 function can be proposed analogously to that for 
NR function (Ito & Roeder 2001). In this model, GATA1-induced activation might start 
by dissociation of PU.1 (a suppressor of GATA1 function) from GATA1, and 
subsequent interaction of DNA-bound GATA1 with either CBP/p300 or Mediator. 
Destabilization of the nucleosome by CBP/p300 may be prerequisite for 
Mediator-facilitated recruitment of RNA polymerase II and formation of the PIC. In this 
model, CCAR1/CoCoA might contribute to the increased mechanistic complexity, 
enabling multiple interfaces for GATA1 to access to both CBP/p300 and MED1 (or 
Mediator). 
 
GATA1 also interacts with several DNA-bound and unbound activators and coactivators 
[e.g., FOG1 (Tsang et al. 1997), KLF-1 (Crossley et al. 1994), Sp1 (Merika & Orkin 
1995), RUNX1 (Elagib et al. 2003), and LMO2 (Wadman et al. 1007)]. Each of these 
factors, and a tetrameric complex of SCL/Tal-1, E2A, LDB1, and LMO2, may, either 
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singly or in combination, contribute to Mediator recruitment and formation of the PIC, 
irrespective of MED1. The residual erythropoiesis in Med1-/- embryos (Ito et al. 2000; 
Stumpf et al. 2006) and residual GATA1-mediated activation of the γ-globin promoter in 
Med1-/- MEFs (Fig. 4B) indicate that GATA1-mediated, MED1-independent Mediator 
recruitment and transcriptional activation occur. The contribution of these 
activators/coactivators might add, in parallel, complexity to GATA1-mediated activation, 
and might modify the multistep model described above in a trans-acting manner. It is 
known that acetylation of GATA1 at lysine residues adjacent to the zinc finger domains 
is required for association with bromodomain protein Brd3 (Lamonica et al. 2011). 
Modification(s) (e.g., acetylation) of GATA1 might also alter affinities for 
CCAR1/CoCoA or the abovementioned activators/coactivators, enabling and facilitating 
a switch of the factors that associate with GATA1. Changes in accessibility of 
CCAR1/CoCoA and MED1 to DNA-bound GATA1 12 to 24 h after induction of 
erythroid differentiation (Fig. 7A, B) might reflect changes in GATA1 modification. 
 
Redundancy and the requirement for direct interaction between GATA1 and 
MED1 
Our study indicates that GATA1- and MED1-mediated transcriptional activation occurs 
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via both GATA1-MED1 direct interaction-dependent and -independent mechanisms, the 
latter of which is mediated by CCAR1/CoCoA; however, the underlying mechanism 
may not be restricted to CCAR1/CoCoA. Multiple GATA1-MED1 pathways may have 
important mechanistic and physiological implications. 
 
First, while the GATA1 CF domain serves as a molecular dock for MED1(681–715), 
CCAR1, CoCoA (Fig. 9), and several activators (Fig. 5C), we do not know whether a 
single GATA1 molecule interacts with all of these simultaneously. Studies of the 
three-dimensional structure suggest that a DNA-bound GATA1 NF domain can bind to 
FOG1 (Liew et al. 2005), and that the GATA1 NF domain binds FOG1 and LMO2 
simultaneously (Wilkinson-White et al. 2011), suggesting that the GATA1 CF domain 
might contain a binding interface for multiple molecules. If this is the case, then GATA1 
CF domain-bound activators/coactivators might contribute to the interaction with 
Mediator via either MED1 or other subunit(s) of Mediator. Another possibility is that 
multiple GATA1 molecules bound to multiple GATA-binding sites of a promoter (e.g., 
the γ-globin promoter has 2 GATA-binding sites.) might bind to different 
activators/coactivators, and eventually the multiplicity of activators/coactivators on the 
same promoter would contribute to a stronger interaction with, and recruitment of, 
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Mediator, and thus might synergize the activator/coactivator signals, eventually 
facilitating PIC formation on the promoter. 
 
Second, the CCAR1/CoCoA pair has multiple functions in GATA1-MED1 interaction, 
namely, (i) direct binding of GATA1 to MED1(681–715), (ii) binding of GATA1 to 
MED1(1–602) via the C-terminus of CCAR1, and (iii) binding of GATA1 to 
MED1(1–602) via CoCoA and subsequently CCAR1. Although the contribution of 
CCAR1/CoCoA appears to be significant, it does not exclude the possibility that other 
cofactor(s) might also play a role in this bypass process. The multiple and redundant 
GATA1-MED1 pathways are reminiscent of the PPARγ2-dependent, and MED1 NR 
box-independent, adipocyte differentiation in cultured cells (Ge et al. 2008), and the 
almost normal development and homeostasis of MED1 NR box-mutant knock-in mice 
(Jiang et al. 2010). However, NR box-dependent activation is specifically necessary in 
some circumstances, as shown by the retarded ERα-dependent pubertal growth of 
mammary epithelial cells in NR box-mutant knock-in mice (Jiang et al. 2010). 
 
The physiological significance of the multiple modes for the nuclear GATA1-MED1 
pathway is not yet known. However, because the intact MED1 is required for maximal 
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transactivation and erythroid differentiation (this study), MED1 is probably required for 
a full GATA1 function in a living animal. Full GATA1 activity is presumably required, 
in erythropoiesis for instance, in some special and extreme circumstances, such as to 
meet physiological needs of erythropoiesis during development and pregnancy, and in 
pathological conditions such as hemolysis and bleeding, and recovery from 
myelosuppression due to chemotherapeutic agents. It would be intriguing to determine 
if there is disordered function(s) in one of the GATA1-mediating molecules in 
megaloblastosis and/or neoplastic diseases such as myelodysplastic syndromes. 
Disordered function(s) in one of these molecules may also result from some disease 
conditions including some types to leukemia where alterations of GATA1 are involved 
(Shimizu et al. 2008). GATA1-mediated homeostatic events other than erythropoiesis 
would also be governed in a likewise manner. The answer to these questions would 
require studies of CCAR1 and/or CoCoA mouse knockouts. 
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EXPERIMENTAL PROCEDURES 
Plasmids 
Mammalian expression vectors pIRESneo-hMED1 (full-length), 
pIRESneo-hMED1(1–602), pIRESneo-hMED1(1–703), and 
pIRESneo-hMED1(592–1,581) (Sumitomo et al. 2010), and CMV-p300 (Gu et al. 
1997) have been described. The cDNAs for mGATA1 and hGATA1 kindly provided by 
M. Yamamoto, and for mCCAR1 and mCoCoA prepared by reverse transcriptase-PCR 
(RT-PCR) using the ReverTra Ace qPCR RT Kit and KOD FX (Toyobo, Japan), were 
cloned in either pIRESneo (Clontech) or pcDNA3.1(+) (Invitrogen) to create 
pIRESneo-mGATA1, pIRESneo-mCCAR1, and pcDNA3.1-mCoCoA, respectively. For 
the expression of glutathione S-transferase (GST)-fusion proteins, cDNAs encoding 
hMED1(534–659), hMED1(637–703), hMED1(681–715), hMED1(691–715), 
hMED1(704–715), hMED1(704–739), mGATA1 (full-length), mGATA1(1–199), 
mGATA1(1–257), mGATA1(200–413), mGATA1(249–413), mGATA1(316–413), 
mGATA1(200–315), mGATA1(249-315), mGATA1(249-330), mCoCoA(1–60), 
mCoCoA(45–125), mCoCoA(93–163), mCoCoA(144–190), mCoCoA(173–270), 
mCoCoA(250–360), mCoCoA(330–426), mCoCoA(410–513), mCoCoA(501–562), 
and mCoCoA(551–691) were amplified by PCR and subcloned into pGEX4T-3 (GE 
34 
 
Healthcare). mGATA1 was HA- and FLAG-tagged, and subcloned into pVL1392 (BD 
Biosciences) to generate pVL-HA-mGATA1 and pVL-FLAG-mGATA1, respectively. 
mCCAR1, mCoCoA, hMED1 (full-length), hMED1(1–552), hMED1(715–1,581), and 
hMED1(1–602) were HA- or FLAG-tagged, and subcloned into either pVL1392 or 
pVL1393 to create pVL-HA-mCCAR1, pVL-HA-mCoCoA, pVL-HA-hMED1, 
pVL-FLAG-hMED(1–552), pVL-FLAG-hMED1(715–1,581) and 
pVL-HA-hMED1(1–602), respectively. For mammalian two-hybrid assays, 
Gal4-hMED1 in pCDM8 (Invitrogen) (pGal4-hMED1) was used, which has been 
described previously (Sumitomo et al. 2010). cDNAs encoding mCCAR1(1–1,146), 
mCCAR1(1–657), mCCAR1(640–1,146), mCoCoA(1–691), mCoCoA(1–500), 
mCoCoA(501–691), and mCoCoA(45–125) were fused to Gal4 and subcloned into 
pCDM8 to generate pGal4-mCCAR1(1–1,146), pGal4-mCCAR1(1–657), 
pGal4-mCCAR1(640–1,146), pGal4-mCoCoA(1–691), pGal4-mCoCoA(1–500), 
pGal4-mCoCoA(501–691), and pGal4-mCoCoA(45–125), respectively. cDNAs 
encoding mCCAR1(1–657), mCCAR1(640–1,146), mGATA1 (full-length), 
mGATA1(1–199), mGATA1(1–257), mGATA1(200–413), mGATA1(249–413), 
mGATA1(316–413), mCCAR1 (full-length), mCCAR1(1–657), and 
mCCAR1(640–1,146) were fused to VP16 and subcloned into pcDNA3.1(+) 
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(Invitrogen) to generate pVP16-mCCAR1(1–657), pVP16-mCCAR1(640–1,146), 
pVP16-mGATA1, pVP16-mGATA1(1–199), pVP16-mGATA1(1–257), 
pVP16-mGATA1(200–413), pVP16-mGATA1(249–413), pVP16-mGATA1(316–413), 
pVP16-mCCAR1, pVP16-mCCAR1(1–657), and pVP16-mCCAR1(640–1,146), 
respectively. Expression vectors for Gal4-fused full-length hGATA1 and for 
VP16-fused various truncations of hGATA1 were likewise prepared. For luciferase 
reporters, the human γ-globin promoter (–299 to +37) was amplified from genomic 
DNA using KOD FX (Toyobo, Japan) and cloned into the firefly luciferase reporter 
plasmid pGL4.10 to create γ-globin-LUC. The reporter containing 5 Gal4 binding sites 
(5uGal4-LUC) has been described (Sumitomo et al. 2010). 
 
Cell culture 
K562 cells (Lozzio & Lozzio 1975), obtained from the Japanese Collection of Research 
Bioresources (Osaka, Japan), were cultured in RPMI1640 supplemented with 10% fetal 
bovine serum (FBS) at 37°C. Erythroid differentiation of K562 cells was induced by the 
addition of 50 μM hemin, and quantified by counting the number of cells that were 
positive for 3,3′-dimethoxybenzidine (MP Biomedicals, Inc.) staining (Lam et al. 2010). 
Stable lines of Med1+/+ p53-/- and Med1-/- p53-/- mouse embryonic fibroblasts (MEFs), 
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established from embryonic day 10.0 (E10.0) embryos derived from a single crossing of 
Med1+/- p53+/- male and Med1+/- p53+/- female mice in a C57BL6 background, have been 
described (Sumitomo et al. 2010). These Med1+/+ and Med1-/- MEFs (in p53-/-) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS at 37°C. 
 
Transient expression and RNA interference 
For transient expression, 1.0 × 106 K562 cells in a 6-well dish were transfected with 5 
Pg of pIRESneo-hMED1, pIRESneo-hMED1(1–602), pIRESneo-hMED1(1–703), 
pIRESneo-mCCAR1 and/or pcDNA3.1-mCoCoA, or empty pIRESneo as a control, 
using LipofectamineTM LTX Reagent (Invitrogen) or Cell Line Solution V with 
Nucleofector II device (Lonza). Hemin was added after 6 h. 
For RNA interference, hMED1 siRNA (Custom siRNA, Qiagen; sense, 
GGCUCUCAAAGUAACAUCUdTdT; antisense, 
AGAUGUUACUUUGAGAGCCdTdT), siRNA for hCoCoA or hGATA1 (Silencer 
select predesigned siRNA; Applied Biosystems), or control siRNA (Invitrogen) (5 nM 
in 24-well plates), was transfected using either Lipofectamine RNAiMAX (Invitrogen) 
or Cell Line Solution V with Nucleofector II devise (Lonza) according to the 
manufacturer’s protocol. Cotransfection of hMED1 siRNA together with 
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siRNA-resistant pIRES-MED1(1–602) (Hasegawa et al. 2012) was performed by using 
Cell Line Solution V with Nucleofector II device (Lonza). 
 
Luciferase reporter assay and mammalian two-hybrid assay 
For luciferase reporter assays, MEFs (2 × 104) in 24-well plates were transfected with 
pIRESneo-hMED1, pIRESneo-hMED1(1–602), pIRESneo-hMED1(1–703), 
pIRESneo-hMED1(592–1,581), pIRESneo-mGATA1, pIRESneo-mCCAR1 and/or 
pcDNA3.1-mCoCoA, together with γ-globin-LUC (50 ng) and the Renilla control 
luciferase vector (5 ng) using Lipofectamine (Invitrogen). Cotransfection of mCCAR1 
siRNA (Silencer select predesigned siRNA; Applied Biosystems) together with 
γ-globin-LUC, pIRESneo-mGATA1, and/or pIRESneo-hMED1(1–602) was performed 
by using Lipofectamine RNAiMAX to introduce siRNA followed by using 
Lipofectamine LTX the next day to introduce plasmids (Invitrogen). After 48 h, reporter 
activity was measured using the Dual-Luciferase Reporter Assay System (Promega) and 
normalized to the activity of the control Renilla luciferase (Sumitomo et al. 2010). 
 
Mammalian two-hybrid assays were similarly performed by transfection with 10 ng of 
Gal4-fused expression vector [pGal4-hMED1, pGal4-m/hGATA1, 
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pGal4-mCCAR1(1–1,146), pGal4-mCCAR1(1–657), pGal4-mCCAR1(640–1,146), 
pGal4-mCoCoA(1–691), pGal4-mCoCoA(1–500), pGal4-mCoCoA(501–691), or 
pGal4-mCoCoA(45–125)], 200 ng of VP16-fused expression vector 
[pVP16-hMED1(1–637), pVP16-hMED1(637–703), pVP16-hMED1(681–715), 
pVP16-hMED1(715–947), pVP16-hMED1(920–1,581), pVP16-mCCAR1(1–657), 
pVP16-mCCAR1(640–1,146), pVP16-mGATA1, pVP16-m/hGATA1(1–199), 
pVP16-m/hGATA1(1–257), pVP16-m/hGATA1(200–413), 
pVP16-m/hGATA1(249–413), pVP16-m/hGATA1(316–413), pVP16-mCCAR1, 
pVP16-mCCAR1(1–657) or pVP16-mCCAR1(640–1,146)], and 5uGal4-LUC (100 ng), 
together with the Renilla control luciferase vector (5 ng). 
 
Quantification of mRNA expression 
For quantitative PCR (qPCR), total RNA (1 μg), extracted with ISOGEN (NIPPON 
GENE, Japan), were used to prepare cDNAs with the ReverTra Ace qPCR RT kit 
(Toyobo, Japan). The expression of various genes was identified by qPCR 
(StepOnePlusTM real-time PCR system; Applied Biosystems). Values were normalized 
to the values of human or mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
measured as a reference marker. The sequences of the primers and the PCR conditions 
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used for amplification are available upon request. 
 
Co-immunoprecipitation and western blot analysis 
For the co-immunoprecipitstion, anti-GATA1 rat polyclonal antibody (N6; Santa Cruz 
Biotechnology) or control IgG were pretreated with Dynabeads Protein G (Life 
Technologies) for 10 min at room temperature. K562 cells were treated with hemin for 2 
days, and total cell lysates in BC150 buffer with 0.1% NP40 and 1 mM 
phenylmethylsulfonyl fluoride were incubated with the protein G-bound antibodies for 
30 min at room temperature, and the bound proteins were isolated. 
 
For the western blot analysis, proteins were separated by SDS-PAGE, blotted onto a 
nitrocellulose membrane, and probed with polyclonal antibodies (Sumitomo et al. 
2010). 
 
In vitro protein-protein interaction analysis 
For bacterial expression, GST-fused proteins were expressed in and purified from 
Escherichia coli strain JM109. For baculovirus-mediated expression, 
pVL-HA-mCCAR1, pVL-HA-mCoCoA, pVL-HA-hMED1, pVL-FLAG-hMED(1–552), 
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pVL-FLAG-hMED1(715–1,581), and pVL-HA-hMED1(1–602) were cotransfected into 
Sf9 cells using BacVector-2000 (Novagen). Whole cell lysates of Sf9 cells expressing 
these recombinant proteins were used in the analyses. 
 
For GST-pull down assays, immobilized GST or GST-fusion protein (1.5 μg) and 3 μL 
of Sf9 cell lysate were used. For co-immunoprecipitation assays, FLAG-tagged 
hMED1(1–552) or hMED1(715–1,581) (1 μg) immobilized to M2 agarose (Sigma) and 
3 μL of Sf9 cell lysate containing HA-tagged GATA1 were used. These were incubated 
in BC150 buffer with 0.1% NP40 and 1 mM β-mercaptoethanol at 4°C for 1 h. Then the 
beads were washed extensively with the binding buffer and bound proteins were eluted 
in 0.3% sarkosyl. Samples were separated by SDS-PAGE, blotted onto a nitrocellulose 
membrane, and probed with either anti-HA (12CA5; Boehringer) or anti-FLAG (M5; 
Sigma) antibody. 
 
ChIP assay 
For ChIP assays, 1.0 × 107 K562 cells (before or after treatment with hemin) were fixed 
with 1% formalin for 10 min and used to prepare chromatin by sonication according to 
the ChIP-IT Express manual (Active Motif). Samples were immunoprecipitated with 
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anti-GATA1, anti-MED1 (M255; Santa Cruz Biotechnology), anti-CCAR1 (ab70244; 
Abcam), and anti-CoCoA (Bethyl Laboratories) antibodies and control IgG (Sigma), 
and used to amplify the γ-globin promoter region, from –299 to +37, by quantitative 
PCR. The sequences of the primers and the PCR conditions used for amplification are 
available upon request. 
 
Statistical analysis 
The significance of differences between independent means was assessed by Student’s t 
test. We considered a P value of <0.05 to be statistically significant. 
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FIGURE LEGENDS 
Figure 1. MED1 requirement for GATA1-targeted gene transcription and erythroid 
differentiation in K562 cells. 
(A) Erythroid differentiation of 3,3′-dimethoxybenzidine-treated cells. Approximately 
45% of cells differentiated after 5 days of treatment. Values (mean ± SD) from a 
representative experiment performed in triplicate are shown. 
(B) Induction of GATA1-targeted gene transcription. Values (mean ± SD) from a 
representative experiment performed in quadruplicate are shown (**p < .01). 
Representative GATA1-targeted genes were induced during cell differentiation. 
(C) Results of quantitative RT-PCR of MED1 (left panel) and MED24 (right panel) are 
shown. Values (mean ± SD) of a representative experiment performed in duplicate 
are plotted (*p < .05, **p < .01). Transcription of the genes encoding the Mediator 
subunits MED1 and MED24 are induced during differentiation of cells. 
(D) Results of quantitative RT-PCR of MED1 after transfection with MED1 or control 
siRNA are shown. Values (mean ± SD) of a representative experiment performed in 
duplicate are shown (**p < .01). si, siRNA. 
(E) Results of western blot analyses of MED1, and TBP as a control, 2 days after 
transfection with MED1 or control siRNA, and siRNA-resistant hMED1(1–602) 
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expression vector are shown. α, anti. 
(F) Reduced GATA1-targeted gene transcription 3 days after transfection with MED1 
siRNA. Simultaneous expression of siRNA-resistant hMED1(1–602) partially 
rescues the GATA1-targeted gene transcription. Values (mean ± SD) of a 
representative experiment performed in quadruplicate are shown (**p < .01). 
(G) Attenuated erythroid differentiation after transfection with MED1 siRNA. The 
siRNA-resistant MED1(1–602) rescues the attenuated erythroid differentiation. 
Control siRNA was used as a control. Values (mean ± SD) of a representative 
experiment performed in quadruplicate are shown (*p < .05, **p < .01). 
The results were reproducible in three independent experiments. 
 
Figure 2. GATA1 physically interacts with MED1(681–715). 
(A) Diagram of MED1, showing 2 nuclear receptor recognition motifs (NR boxes; NR1 
and NR2) and the fragments used in this study. 
(B) Fragments of FLAG-tagged MED1 were incubated with HA-tagged GATA1 and 
immunoprecipitated with M2-agarose. HA-GATA1 was visualized with an anti-HA 
antibody. 
(C) GST-pull down assays using GST-fused to various MED1 fragments and 
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FLAG-tagged GATA1. An anti-FLAG antibody was used to visualize 
FLAG-GATA1. 
(D, E) Mammalian two-hybrid assays. Luciferase activity of the reporter with 5u 
Gal4-binding sites was measured. Gal4-fused mGATA1 (D) and Gal4-fused 
hGATA1 (E) interact with VP16-fused hMED1(681–715). Values (mean ± SD) of a 
representative experiment performed in duplicate (D) or triplicate (E) are shown. 
 
Figure 3. MED1(1–602) and MED1(1–703) induce GATA1-mediated transcription and 
erythroid differentiation in K562 cells. 
(A) Diagram of MED1, showing the domains of 2 NR boxes (NR1 and NR2) and the 
GATA1 binding domain and the MED1 fragments used in these experiments. 
(B, C) Results of quantitative RT-PCR for MED1 (B) and western blot analyses for 
Mediator subunits and TBP as a control (C) 3 days after transfection with 
expression vectors with various fragments of MED1 or an empty expression vector 
as a control in hemin-treated K562 cells. Values (mean ± SD) of a representative 
experiment performed in duplicate are shown (**p < .01) (B). 
(D) Enhanced GATA1-targeted gene transcription after overexpression of various 
fragments of MED1 or an empty expression vector as a control in hemin-treated 
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cells. Values (mean ± SD) of a representative experiment performed in 
quadruplicate are shown (*p < .05, **p < .01). 
(E) Enhanced erythroid differentiation after overexpression of various MED1 fragments 
in hemin-treated cells. An empty expression vector was used as a control. Values 
(mean ± SD) of a representative experiment performed in triplicate are plotted (*p 
< .05, **p < .01). 
The results were reproducible in three independent experiments. 
 
Figure 4. N-terminal MED1 and CCAR1 drive GATA1-mediated transcription from the 
γ-globin promoter. Luciferase reporter assays of the human γ-globin promoter in MEFs 
are shown. 
(A)  GATA1-dependent transcriptional activation of the γ-globin promoter in Med1+/+ 
MEFs in the presence of 10, 50, 100, and 200 ng of GATA1. 
(B) GATA1-dependent and MED1-mediated transcriptional activation. The amounts of 
the expression vectors added are as follows: 100 ng of GATA1 and 10 or 100 ng of 
various MED1 fragments. 
(C) CCAR1-enhanced activation of GATA1-dependent transcription in Med1+/+ MEFs. 
The amounts of expression vectors added are as follows: 20 ng of GATA1, 20 or 100 
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ng of CCAR1, and 100 ng of p300 (*p < .05, **p < .01). 
(D) Mammalian two-hybrid assays. Luciferase activities of the reporter with 5u 
Gal4-binding sites are measured. Gal4-fused MED1 interacts with VP16-fused 
CCAR1(1–657) and CCAR1(640–1,146). 
Values (mean ± SD) of a representative experiment performed in duplicate are 
shown (A-D). The results were reproducible in three independent experiments. 
 
Figure 5. The CF domain of GATA1 is necessary for the direct interaction with 
CCAR1(640–1,146) and MED1. 
(A, D, F, I) GST-pull down assays. HA-CCAR1 (A, D, I) or HA-MED1 (F, I) is pulled 
down by various GST-fusion fragments of GATA1. HA-CCAR1 and HA-MED1 
were visualized with an anti-HA antibody. 
(B, E, G, H) Mammalian two-hybrid assays. Luciferase activities of a reporter with 
5uGal4-binding sites were measured. The interaction between various Gal4-fusion 
fragments of mCCAR1 (B, E) or hMED1 (G, H) and various VP16-fusion fragments 
of mGATA1 (B, E, G) or hGATA1 (H) were tested. Values (mean ± SD) of a 
representative experiment performed in duplicate (B, E, G) or triplicate (H) are 
shown. The results were reproducible in three independent experiments. 
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(C) Diagram of mGATA1, showing the 2 zinc-finger domains, NF and CF, and the 
transcription factors that interact with these zinc finger domains, as well as the 
fragments used in these experiments. 
 
Figure 6. The AD1 domain of CoCoA interacts with CCAR1(501–691), while the AD2 
domain of CoCoA interacts with the GATA1 CF domain. 
(A, B, E, G) Mammalian two-hybrid assays. The luciferase activity of the reporter with 
5uGal4-binding sites was measured. The interaction between various Gal4-fusion 
fragments of CoCoA (A, B, E, G) and various VP16-fusion fragments of CCAR1 (A, 
B) or GATA1 (E, G) were tested. Values (mean ± SD) of a representative experiment 
performed in duplicate are shown. The results were reproducible in three 
independent experiments. 
(C, D, F) GST-pull down assays. HA-CoCoA (C, D) or FLAG-GATA1 (F) was pulled 
down by various GST-fusion fragments of GATA1 (C, D) or CoCoA (F). HA-CoCoA 
and FLAG-GATA1 were visualized using an anti-HA or -FLAG antibody, 
respectively. 
(H) Diagram of CoCoA showing the activation domains AD1 and AD2, the coiled-coil 
domain, and the leucine zippers. Transcription factors that interact with these 
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domains are also shown. 
 
Figure 7. GATA1, MED1, CCAR1 and CoCoA are recruited onto the γ-globin promoter 
during erythroid differentiation of K562 cells. 
(A, B) ChIP assays showing the occupancies of GATA1, MED1, CCAR1, and CoCoA 
on the γ-globin promoter during 3 days (A) and 24 h (B) of erythroid differentiation 
of hemin-treated K562 cells. 
(C, D) Results of quantitative RT-PCR (C) and western blot analyses (D) of GATA1 2 
days after transfection with GATA1 siRNA in K562 cells are shown. Values (mean ± 
SD) of a representative experiment performed in triplicate are shown (**p < .01). 
(E) ChIP assays of hemin-treated K562 cells showing the occupancies of indicated 
cofactors on the γ-globin promoter before and 3 days after transfection with GATA1 
siRNA. 
Unimmunized rabbit IgG is used as a negative control. Values (mean ± SD from a 
representative experiment performed in triplicate) are plotted as percentages of the 
value of the input (A, B, E). The results were reproducible in three independent 
experiments. 
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Figure 8. CCAR1 and CoCoA cooperatively enhance GATA1- and MED1-mediated 
transcriptional activation of the γ-globin promoter. 
(A) GST-pull down assay. The interaction between baculovirus expressed CCAR1, 
CoCoA, and/or MED1(1–602), and bacterially expressed GST-GATA1(200–315) 
(lanes 2-4) or GST (lanes 5-7) was tested. GATA1(200–315), CCAR1, and CoCoA 
form a ternary complex (lane 2), and the addition of CoCoA enables formation of a 
tetramer complex (lane 3). 
(B) Coimmunoprecipitation of K562 cells treated with hemin for 2 days. Endogenous 
CCAR1 and CoCoA are co-immunoprecipitated together with endogenous GATA1. 
Anti-CCAR1, anti-CoCoA, anti-MED1, or anti-GATA1 antibody was used (A, B). 
(C, D) Luciferase reporter assays of the human γ-globin promoter in Med1+/+ (C, D) and 
Med1-/- (D) MEFs. (C) CoCoA dose-dependently enhances GATA1-mediated 
transcriptional activation. The amounts of each expression vector added were as 
follows: 20, 50, or 100 ng of CoCoA and 20 ng of GATA1. (D) CCAR1 and CoCoA 
synergistically enhance GATA1-mediated transcriptional activation in a 
MED1-dependent manner. The amounts of each expression vector added were as 
follows: 20 ng of GATA1, 20 ng of CoCoA, and 20 ng of CCAR1.  
(E) Overexpression of CCAR1 and/or CoCoA in hemin-treated K562 cells. The mRNA 
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expression of GATA1-targeted genes 3 days after transfection with the CCAR1 
and/or CoCoA expression vectors is shown. An empty expression vector was used as 
a control. 
(F, G) Results of quantitative RT-PCR (F) and western blot analyses (G) of GATA1 2 
days after transfection with hCoCoA siRNA in K562 cells are shown. Anti-TBP 
antibody was used as a control (G). 
(H) GATA1-targeted gene transcription 3 days after transfection with hCoCoA siRNA in 
hemin-treated K562 cells. 
(I, J) Results of quantitative RT-PCR (I) and western blot analyses (J) of GATA1 2 days 
after transfection with mCCAR1 siRNA in Med1-/- MEFs are shown. Anti-TBP 
antibody was used as a control (J). 
(K) Luciferase reporter assays of the human γ-globin promoter in Med1-/- MEFs. 
Knockdown of CCAR1 prominently reduces GATA1- and MED1(1-602)-mediated 
transcriptional activation. 
Values (mean ± SD) of a representative experiment performed in duplicate (C, D) or 
triplicate (E, F, I, H, K) are shown (*p < .05, **p < .01). The results were reproducible 
in three independent experiments. 
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Figure 9. Proposed model for the role of CCAR/CoCoA in the bypass mechanism of 
GATA1- and MED1-mediated transcriptional activation. CCAR1, CoCoA, and 
MED1(681–715) interact with the CF domain either competitively or simultaneously. 
CCAR1 and CoCoA interact with the CF domain of GATA1 and the N-terminal domain 
of MED1 simultaneously via multiple interfaces. MED1-led Mediator then recruits 
RNA polymerase II, eventually forming a preinitiation complex for transcription 
initiation. The multiple pathways that underlie the GATA1-MED1 axis may help to 
fine-tune the coupling between GATA1 and the basal transcriptional machinery. 
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LEGENDS TO SUPPORTING FIGURES 
 
Figure S1. RT-PCR of GATA1 and GATA1-associated activators and coactivators in 
hemin-treated K562 cells. Values (mean ± SD) of a representative experiment 
performed in triplicate are shown (*p < .05, **p < .01). 
 
Figure S2. RT-PCR of GATA1 and GATA1-associated activators and coactivators 3 days 
after transfection with hMED1 or control siRNA in hemin-treated K562 cells. Values 
(mean ± SD) of a representative experiment performed in triplicate are shown (*p < .05, 
**p < .01). 
 
Figure S3. Reduced GATA1-targeted gene transcription 3 days after transfection with 
hMED1 or control siRNA in hemin-untreated K562 cells. Values (mean ± SD) of a 
representative experiment performed in triplicate are shown (**p < .01). 
 
Figure S4. Recombinant proteins. 
(A) Western blot analyses of baculovirus expressed FLAG-tagged MED1 truncations. 
Anti-FLAG antibody was used. 
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(B) Coomassie staining of GST and GST-fused MED1 truncations. 0.5 μg (GST-fused 
MED1(534–659), MED1(681–715), MED1(691–715)) or 1 μg (others) of proteins 
are shown. 
 
Figure S5. RT-PCR of GATA1 and GATA1-associated activators and coactivators in 
hemin-treated K562 cells 3 days after transfection with MED1(1–602) or control empty 
expression vector. Values (mean ± SD) of a representative experiment performed in 
triplicate are shown (*p < .05, **p < .01). 
 
Figure S6. RT-PCR of GATA1-targeted gene products, GATA1, and GATA1-associated 
activators and coactivators in hemin-untreated K562 cells 3 days after transfection with 
MED1(1–602) or control empty expression vector. Values (mean ± SD) of a 
representative experiment performed in triplicate are shown (**p < .01). 
 
Figure S7. RT-PCR of MED1, CCAR1 and CoCoA in K562 cells 3 days after 
transfection with hGATA1 or control siRNA. Values (mean ± SD) of a representative 
experiment performed in triplicate are shown (*p < .05, **p < .01). 
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Figure S8. Western blot analyses of CCAR1 and/or CoCoA overexpression in K562 
cells. Anti-CCAR1 and anti-CoCoA antibodies, and anti-TBP antibody as a control, 
were used. 
 
Figure S9. RT-PCR of GATA1-associated activators in hemin-treated K562 cells 3 days 
after transfection with CCAR1, CoCoA and/or control empty expression vectors. Values 
(mean ± SD) of a representative experiment performed in triplicate are shown (*p < .05, 
**p < .01). 
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